Ascletis Pharma, Inc. (1672) AI Stock Analysis

• Market Cap: HK$6.35B
• Dividend Yield: N/A
• Average Volume (3M): 7.00M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.89
• Revenue Growth: -97.81%
• EPS Growth: -117.20%
• Country: HK
• Employees: 231
• Sector: Healthcare
• Sector Strength: 57
• Industry: Biotechnology
• EPS (TTM): -0.33
• Shares Outstanding: 969,430,500
• 10 Day Avg. Volume: 4,802,036
• 30 Day Avg. Volume: 7,004,231
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$3.94
• Price Target Upside: -39.85% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

Ascletis Pharma's overall score reflects the company's financial instability, particularly in income and cash flow, balanced by a strong balance sheet. While technical analysis shows mixed signals, the stock's valuation remains a concern with negative earnings. The company needs to address profitability and cash flow issues to improve its financial health and stock performance.

Ascletis Pharma, Inc. Business Overview & Revenue Model

Company Description

Ascletis Pharma, Inc. (1672) is a leading biotechnology company headquartered in China, focused on the development and commercialization of innovative drugs for the treatment of liver diseases, viral infections, and cancer. The company is dedicated to improving human health through its robust pipeline of proprietary therapies and strategic partnerships with global pharmaceutical firms.

How the Company Makes Money

Ascletis Pharma, Inc. generates revenue primarily through the development and commercialization of its pharmaceutical products. The company earns money by researching, developing, and bringing to market innovative drugs, particularly in the areas of liver diseases, viral infections, and oncology. Key revenue streams include sales of proprietary drugs, milestone payments, and royalties from partnerships with other pharmaceutical companies. Ascletis also engages in licensing agreements and collaborations with global pharmaceutical firms, which provide additional income through upfront payments and ongoing royalties based on the success of co-developed therapies.

Ascletis Pharma, Inc. Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
56.60M	54.09M	76.88M	35.00M	173.44M
	Gross Profit
25.99M	-24.69M	39.17M	-23.50M	124.28M
	EBIT
-306.81M	-262.82M	-195.90M	-156.43M	-36.44M
	EBITDA
-126.09M	-284.50M	-169.35M	-181.94M	-73.64M
	Net Income Common Stockholders
-144.72M	-366.71M	-202.14M	-262.05M	-155.50M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
2.30B	2.48B	2.50B	2.71B	2.99B
	Total Assets
2.49B	2.66B	2.83B	3.07B	3.43B
	Total Debt
8.42M	4.24M	2.75M	1.59M	3.81M
	Net Debt
-321.70M	-2.47B	-2.49B	-2.71B	-2.99B
	Total Liabilities
148.94M	117.16M	100.89M	85.42M	102.17M
	Stockholders Equity
2.34B	2.54B	2.73B	2.98B	3.32B
Cash Flow		Free Cash Flow
-163.32M	-156.85M	-154.13M	-123.87M	-102.57M
	Operating Cash Flow
-144.16M	-142.45M	-146.93M	-84.91M	-74.34M
	Investing Cash Flow
149.84M	-1.30B	-274.49M	132.30M	602.27M
	Financing Cash Flow
-81.50M	-1.42M	-31.10M	-21.67M	-48.22M

Ascletis Pharma, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6.55
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1672, the sentiment is Positive. The current price of 6.55 is above the 20-day moving average (MA) of 6.07, below the 50-day MA of 6.80, and above the 200-day MA of 3.09, indicating a neutral trend. The MACD of -0.10 indicates Negative momentum. The RSI at 51.30 is Neutral, neither overbought nor oversold. The STOCH value of 74.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1672.

Ascletis Pharma, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2318	72 Outperform	$926.38B	6.69		5.29%	11.71%	37.04%
1877	54 Neutral	HK$28.32B	―	-19.78%	―	25.96%	39.58%
Sector *	52 Neutral	$5.35B	3.96	-42.60%	2.86%	17.58%	1.27%
1672	51 Neutral	HK$6.35B	―	-13.97%	―	-97.81%	-117.20%

Ascletis Pharma, Inc. Corporate Events

Ascletis Pharma Announces 2025 Annual General Meeting Agenda

Ascletis Pharma Inc. has announced its 2025 Annual General Meeting, scheduled for May 22, 2025, in Hangzhou, China. The meeting will address several key business items, including the consideration of the company’s audited financial statements for 2024, the re-election of directors, and the re-appointment of KPMG as the auditor. Additionally, resolutions will be proposed to authorize the company’s board to manage share allotments and repurchases, potentially impacting the company’s capital structure and shareholder value.

Ascletis Pharma Reports Positive Phase Ib Results for ASC30 in Obesity Treatment

Ascletis Pharma Inc. announced positive results from its Phase Ib study of ASC30, a small molecule oral GLP-1 receptor agonist, which showed significant body weight reduction in participants with obesity. The study supports a ‘lower starting dose and slower titration’ strategy for the upcoming Phase IIa study, which has been submitted to the FDA, indicating potential advancements in obesity treatment and reinforcing Ascletis’s position in the pharmaceutical industry.

Ascletis Pharma Reports Promising Phase Ib Results for ASC30 in Obesity Treatment

Ascletis Pharma Inc. announced positive interim results from its U.S. Phase Ib trial of ASC30, a potentially first-in-class subcutaneous injection small molecule GLP-1R agonist. The trial demonstrated a 36-day half-life for one formulation, supporting less frequent administration, and showed a favorable safety profile with no serious adverse events. This advancement could enhance Ascletis’ positioning in the obesity treatment market, offering a novel therapeutic option with both oral and injectable formulations.

Ascletis Pharma Reports Increased R&D Investment Amid 2024 Financial Results

Ascletis Pharma Inc. announced its annual results for 2024, revealing a significant increase in R&D expenses due to its focus on developing treatments for obesity and metabolic diseases. Despite a substantial loss for the year, the company has sufficient cash reserves to support its operations and R&D activities until 2029, highlighting its commitment to advancing its pipeline and maintaining a competitive edge in the biomedical industry.

Ascletis Pharma Reports Positive Phase Ib Results for ASC47 and FDA Clearance for Combination Study

Ascletis Pharma Inc. announced positive results from its Phase Ib studies of ASC47, a weight loss drug candidate, demonstrating a significant half-life and good tolerability in both healthy subjects and patients with obesity. The U.S. FDA has cleared the IND application for ASC47 in combination with semaglutide, potentially enhancing the company’s positioning in the obesity treatment market by offering a promising new therapy option.

Ascletis Pharma Reports Positive Interim Results for ASC30 Obesity Treatment

Ascletis Pharma Inc. announced positive interim results from its U.S. Phase Ib study of the ASC30 oral tablet, showing significant mean body weight reductions in patients with obesity. The ASC30 tablet was well tolerated, with no serious adverse events reported, enhancing its potential as a promising treatment for obesity. This advancement strengthens Ascletis’s position in the pharmaceutical industry and could have significant implications for stakeholders and the obesity treatment market.